secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001104659-25-089558
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period
--------------------------------------------------------------------------------

- Nasdaq notified Adaptimmune on Sept 11, 2025 that MVLS was below $35M minimum for 32 consecutive business days.
- Company also fails alternative continued listing standards: equity below $2.5M or net income below $500K.
- Has 180 calendar days (until March 10, 2026) to regain MVLS compliance for at least 10 consecutive business days.
- No immediate effect on ADAP ADS trading; failure to comply may result in delisting with appeal option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/0001104659-25-089558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/adap-20250911x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-089558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer